-
CSCO 2025 | Professor Ma Jun: 120 Years of Chinese Hematology Establishing a Global Benchmark – CSCO Annual Meeting to Decode Innovative Therapies and Cutting-Edge Breakthroughs
In the field of hematologic malignancies, top experts from China and abroad will present a rich scientific program covering lymphoma, myeloma, leukemia, and other core diseases. The agenda will feature…
-
TCT Literature Express | Professors Ke Xiaoyan and Hu Kai: Preemptive CD20 CAR-T Therapy Prolongs Survival in Partial Responders after CD19 CAR-T
CD20 is widely expressed on the surface of B cells and represents an attractive therapeutic target for CAR-T therapy. CD20 CAR-T therapy has already demonstrated encouraging efficacy in patients with…
-
ISEH 2025 | Professor Xue Feng: AAV Vector Gene Therapy Driving Innovation in Hemophilia B Treatment in China
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held in Kumamoto, Japan, from September 24 to 27. The event brought together leading global experts to discuss cutting-edge advances in basic hematology, immunology, stem cell biology, and cellular and gene therapies. One of the highlights of the meeting was…
-
CSCO Experts’ Voice | Professor Jianming Guo: Outlook on the Development of China’s Prostate Cancer MDT Model and the Future of AI Applications
Building a Functional MDT for Prostate Cancer Care Q: Prostate cancer MDT involves urology, medical oncology, radiation oncology, pathology, and other specialties. How do you ensure efficient collaboration and avoid…
-
CSCO Experts’ Voice | Professor Xinan Sheng on China-Tailored RCC Guidelines and Innovative Therapies
01 Oncology Frontier – Urology Frontier: As a standing member and secretary-general of the CSCO RCC Expert Committee, you have helped draft and update multiple guideline editions. Could you share…
Connecting Medical Expertise through Media